<DOC>
	<DOCNO>NCT00521131</DOCNO>
	<brief_summary>Evaluation Efficacy Safety Levocetirizine Subjects With Perennial Allergic Rhinitis House Dust Mites</brief_summary>
	<brief_title>Evaluation Efficacy Safety Levocetirizine Subjects With Perennial Allergic Rhinitis House Dust Mites</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>male female ≥ 12 year suffer perennial allergic rhinitis house dust mites least 2 year positive skin test positive RadioAllergoSorbentTest house dust mite mean T4SS evaluate even last 24 hour selection period ≥ 5 seasonal allergic rhinitis likely change significantly symptom subject ear , nose throat ( ENT ) infection two week precede initial visit asthma require corticosteroid treatment atopic dermatitis urticaria require antihistamine treatment administration oral topical corticosteroid associate ENT disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levocetirizine dihydrochloride</keyword>
	<keyword>Xyzal tablet</keyword>
</DOC>